Targeting Cancer-promoting Inflammation - Have Anti-inflammatory Therapies Come of Age?

Overview

Journal Nat Rev Clin Oncol

Specialty Oncology

Date 2021 Jan 20

PMID 33469195

Citations 132

Authors

Jiajie Hou

Michael Karin

Beicheng Sun

Affiliations

Soon will be listed here.

Abstract

The immune system has crucial roles in cancer development and treatment. Whereas adaptive immunity can prevent or constrain cancer through immunosurveillance, innate immunity and inflammation often promote tumorigenesis and malignant progression of nascent cancer. The past decade has witnessed the translation of knowledge derived from preclinical studies of antitumour immunity into clinically effective, approved immunotherapies for cancer. By contrast, the successful implementation of treatments that target cancer-associated inflammation is still awaited. Anti-inflammatory agents have the potential to not only prevent or delay cancer onset but also to improve the efficacy of conventional therapeutics and next-generation immunotherapies. Herein, we review the current clinical advances and experimental findings supporting the utility of an anti-inflammatory approach to the treatment of solid malignancies. Gaining a better mechanistic understanding of the mode of action of anti-inflammatory agents and designing more effective treatment combinations would advance the clinical application of this therapeutic approach.

Citing Articles

TANK-Binding Kinase 1 in the Pathogenesis and Treatment of Inflammation-Related Diseases.

Hui L, Chen X, Huang M, Jiang Y, Liu T Int J Mol Sci. 2025; 26(5).

PMID: 40076567 PMC: 11900955. DOI: 10.3390/ijms26051941.

Epigenetic regulation of transcription factors involved in NLRP3 inflammasome and NF-kB signaling pathways.

Kaszycki J, Kim M Front Immunol. 2025; 16:1529756.

PMID: 40046056 PMC: 11879833. DOI: 10.3389/fimmu.2025.1529756.

Combination therapy with lipid prodrug liposomes reshapes disease-associated neutrophils to promote the cancer-immunity cycle.

Sui D, Song Y, Deng Y J Nanobiotechnology. 2025; 23(1):132.

PMID: 39987076 PMC: 11846314. DOI: 10.1186/s12951-025-03179-3.

Interaction between sleep duration and physical activity on mortality among cancer survivors: findings from National Health and Nutrition Examination Surveys 2007-2018.

Chen R, Han J, Li S, Deng H, Jian T, Huang Z Front Public Health. 2025; 13:1532320.

PMID: 39896788 PMC: 11782222. DOI: 10.3389/fpubh.2025.1532320.

Unveiling the link between chronic inflammation and cancer.

Tripathi S, Sharma Y, Kumar D Metabol Open. 2025; 25:100347.

PMID: 39876904 PMC: 11772974. DOI: 10.1016/j.metop.2025.100347.

References

Calcinotto A, Spataro C, Zagato E, Di Mitri D, Gil V, Crespo M . IL-23 secreted by myeloid cells drives castration-resistant prostate cancer. Nature. 2018; 559(7714):363-369. PMC: 6461206. DOI: 10.1038/s41586-018-0266-0. View

Albrengues J, Shields M, Ng D, Park C, Ambrico A, Poindexter M . Neutrophil extracellular traps produced during inflammation awaken dormant cancer cells in mice. Science. 2018; 361(6409). PMC: 6777850. DOI: 10.1126/science.aao4227. View

McLaughlin M, Patin E, Pedersen M, Wilkins A, Dillon M, Melcher A . Inflammatory microenvironment remodelling by tumour cells after radiotherapy. Nat Rev Cancer. 2020; 20(4):203-217. DOI: 10.1038/s41568-020-0246-1. View

Castano Z, San Juan B, Spiegel A, Pant A, DeCristo M, Laszewski T . IL-1β inflammatory response driven by primary breast cancer prevents metastasis-initiating cell colonization. Nat Cell Biol. 2018; 20(9):1084-1097. PMC: 6511979. DOI: 10.1038/s41556-018-0173-5. View

Hickish T, Andre T, Wyrwicz L, Saunders M, Sarosiek T, Kocsis J . MABp1 as a novel antibody treatment for advanced colorectal cancer: a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol. 2017; 18(2):192-201. DOI: 10.1016/S1470-2045(17)30006-2. View

Joharatnam-Hogan N, Cafferty F, Hubner R, Swinson D, Sothi S, Gupta K . Aspirin as an adjuvant treatment for cancer: feasibility results from the Add-Aspirin randomised trial. Lancet Gastroenterol Hepatol. 2019; 4(11):854-862. DOI: 10.1016/S2468-1253(19)30289-4. View

Xia D, Wang D, Kim S, Katoh H, DuBois R . Prostaglandin E2 promotes intestinal tumor growth via DNA methylation. Nat Med. 2012; 18(2):224-6. PMC: 3274627. DOI: 10.1038/nm.2608. View

Ambrosone C, Zirpoli G, Hutson A, McCann W, McCann S, Barlow W . Dietary Supplement Use During Chemotherapy and Survival Outcomes of Patients With Breast Cancer Enrolled in a Cooperative Group Clinical Trial (SWOG S0221). J Clin Oncol. 2019; 38(8):804-814. PMC: 7062457. DOI: 10.1200/JCO.19.01203. View

Xiao Q, Wu J, Wang W, Chen S, Zheng Y, Yu X . DKK2 imparts tumor immunity evasion through β-catenin-independent suppression of cytotoxic immune-cell activation. Nat Med. 2018; 24(3):262-270. PMC: 5840007. DOI: 10.1038/nm.4496. View

10.

Feldman D, Krishnan A, Swami S, Giovannucci E, Feldman B . The role of vitamin D in reducing cancer risk and progression. Nat Rev Cancer. 2014; 14(5):342-57. DOI: 10.1038/nrc3691. View

11.

Ben Sahra I, Laurent K, Loubat A, Giorgetti-Peraldi S, Colosetti P, Auberger P . The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level. Oncogene. 2008; 27(25):3576-86. DOI: 10.1038/sj.onc.1211024. View

12.

Cooper J, Giancotti F . Integrin Signaling in Cancer: Mechanotransduction, Stemness, Epithelial Plasticity, and Therapeutic Resistance. Cancer Cell. 2019; 35(3):347-367. PMC: 6684107. DOI: 10.1016/j.ccell.2019.01.007. View

13.

Ma C, Han M, Heinrich B, Fu Q, Zhang Q, Sandhu M . Gut microbiome-mediated bile acid metabolism regulates liver cancer via NKT cells. Science. 2018; 360(6391). PMC: 6407885. DOI: 10.1126/science.aan5931. View

14.

Higurashi T, Hosono K, Takahashi H, Komiya Y, Umezawa S, Sakai E . Metformin for chemoprevention of metachronous colorectal adenoma or polyps in post-polypectomy patients without diabetes: a multicentre double-blind, placebo-controlled, randomised phase 3 trial. Lancet Oncol. 2016; 17(4):475-483. DOI: 10.1016/S1470-2045(15)00565-3. View

15.

Hong D, Hui D, Bruera E, Janku F, Naing A, Falchook G . MABp1, a first-in-class true human antibody targeting interleukin-1α in refractory cancers: an open-label, phase 1 dose-escalation and expansion study. Lancet Oncol. 2014; 15(6):656-66. DOI: 10.1016/S1470-2045(14)70155-X. View

16.

Kang S, Tanaka T, Narazaki M, Kishimoto T . Targeting Interleukin-6 Signaling in Clinic. Immunity. 2019; 50(4):1007-1023. DOI: 10.1016/j.immuni.2019.03.026. View

17.

Ozdemir B, Pentcheva-Hoang T, Carstens J, Zheng X, Wu C, Simpson T . Depletion of carcinoma-associated fibroblasts and fibrosis induces immunosuppression and accelerates pancreas cancer with reduced survival. Cancer Cell. 2014; 25(6):719-34. PMC: 4180632. DOI: 10.1016/j.ccr.2014.04.005. View

18.

Shalapour S, Lin X, Bastian I, Brain J, Burt A, Aksenov A . Inflammation-induced IgA+ cells dismantle anti-liver cancer immunity. Nature. 2017; 551(7680):340-345. PMC: 5884449. DOI: 10.1038/nature24302. View

19.

Ma H, Yamamoto G, Xu J, Liu X, Karin D, Kim J . IL-17 signaling in steatotic hepatocytes and macrophages promotes hepatocellular carcinoma in alcohol-related liver disease. J Hepatol. 2020; 72(5):946-959. PMC: 7167339. DOI: 10.1016/j.jhep.2019.12.016. View

20.

Finlay B, Goldszmid R, Honda K, Trinchieri G, Wargo J, Zitvogel L . Can we harness the microbiota to enhance the efficacy of cancer immunotherapy?. Nat Rev Immunol. 2020; 20(9):522-528. DOI: 10.1038/s41577-020-0374-6. View